Table 4.
Some major ongoing clinical trials on CAR T-cell therapy in blood and solid cancers.
| Clinical trial | Target | Cancer type | Phase | Updated result/status |
|---|---|---|---|---|
| Hematological malignancies | ||||
| NCT03277729 | CD20 | R/R B-NHL | Phase 1/2 | High overall and complete response with an extremely favorable safety profile in B-NHL.188 |
| NCT03262298 | CD22 | R/R B-ALL | Phase 1/2 | Dose-dependent antileukemic activity was observed by targeting CD22 in B-ALL.182 |
| NCT02690545, NCT02917083) | CD30 | R/R HL | Phase 1/2 | It shows an ORR of 72% and a CR rate of 59% in R/R HL with an excellent safety profile.118 |
| NCT02203825 | NKG2D | R/R AML | Phase 1 | Targeting NKG2D-Ligands observed to result in high efficacy against AML.189 |
| NCT03971799 | CD33 | R/R AML | phase 1/2 | Recruiting |
| NCT04014881 | CD123 | R/R AML | Phase 1 | Recruiting |
| NCT04010877 | CLL-1/CD123/CD33 | R/R AML | Phase 1/2 | Recruiting |
| NCT05023707 | FLT3 | R/R AML | Phase 1/2 | The potent In vitro antitumor activities of Flt3-CAR T-cells, combined with their low off-target cytotoxicity, offer hope in the treatment of AML.190 |
| NCT02842320 | IL-1RAP | CML | CAR T-cell therapy exhibited cytotoxicity against leukemic cells expressing IL-1RAP.191 | |
| NCT04689659 | CD7 | R/R T- ALL | Phase 1/2 | Phase 1 trial indicated CD7-targeted CAR T-cells result in efficient expansion and achieved a high CR rate with manageable safety profiles.183 |
| NCT02203825 | NKG2D | R/R T-ALL, AML, MDS, MM | Phase 1 | Targeting NKG2D-Ligands shows robust efficacy against T-ALL.189 |
| NCT04351022 | CD38 | R/R AML | Phase 1/2 | 66.7% patient achieved CR with OS of 7.9 months.192 |
| NCT03081910 | CD5 | R/R T-NHL | Phase 1 | CD5 CAR T-cells are safe and can induce clinical responses in heavily treated patients with R/R CD5+ T-NHL.193 |
| NCT04712864 | CD4 | R/R T-cell lymphoma | Phase 1 | CD4CART-cells have potent cytotoxic effects on T-cell lymphoma.194 |
| NCT04594135 | CD5 | T-ALL | Phase 1 | CD5 CAR T-cells eradicate T-ALL blasts In vitro and control disease progression in xenograft mouse models of T-ALL.195 |
| Solid malignancies | ||||
| NCT03500991 | HER2 | CNS tumor | Phase 1 | HER2-specific CAR T-cells is well tolerated and activate a localized immune response in pediatric and young adult patients.196 |
| NCT03618381 | EGFR806 | Advanced solid cancers | Phase 1 | Recruiting |
| NCT03525782 | MUC1/PD-1 | NSCLC | Phase 1/2 | Recruiting |
| NCT03198052 | PSCA/MUC1/TGFβ, HER2/Mesothelin, Lewis-Y/GPC3/AXL/EGFR, Claudin18.2/B7H3 | Lung cancer | Phase 1 | Recruiting |
| NCT04099797 | GD2 | Brain cancer | Phase 1 | Recruiting |
| NCT02932956 | GPC3 | Liver cancer | Phase 1 | Active but not recruiting |
| NCT01583686 | Mesothelin | Ovarian, cervical, pancreatic, lung cancer | Phase 1/2 | Recruiting |
| NCT02349724 | CEA | Lung, colorectal, gastric, breast, pancreatic cancer | Phase 1 | Recruiting |
| NCT04483778 | B7H3, CD19 | Advanced solid tumors | Phase 1 | Recruiting |
| NCT04025216 | TnMUC1 | R/R solid cancers | Phase 1 | Active but not recruiting |
Abbreviations: ALL, Acute lymphoblastic leukemia; AML, Acute Myeloid Leukemia; CEA, carcinoembryonic antigen; CLL-1, C-type lectin-like molecule-1; CML, Chronic Myeloid Leukemia; CNS, central nervous system; EGFR, Epidermal growth factor receptor; GPC3, Glypican-3 IL1RAP, HL, Hodgkin’s Lymphoma; IL1 receptor-associated protein; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin’s Lymphoma; NKG2D, Natural killer group 2D; NSCLC, Non-small cell lung cancer; PSCA, Prostate stem cell antigen